|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections显示文摘Antibiotic-associated diarrhea(AAD) and Clostridum difficile infections(CDI) have been well studied for adult cases, but not as well in the pediatric population. Whether the disease process or response to treatments differs between pediatric and adult patients is an important clinical concern when following global guidelines based largely on adult patients. A systematic review of the literature using databases Pub Med(June 3, 1978-2015) was conducted to compare AAD and CDI in pediatric and adult populations and determine significant differences and similarities that might impact clinical decisions. In general, pediatric AAD and CDI have a more rapid onset of symptoms, a shorter duration of disease and fewer CDI complications(required surgeries and extended hospitalizations) than in adults. Children experience more community-associated CDI and are associated with smaller outbreaks than adult cases of CDI. The ribotype NAP1/027/BI is more common in adults than children. Children and adults share some similar risk factors, but adults have more complex risk factor profiles associated with more co-morbidities, types of disruptive factors and a wider range of exposures to C. difficile in the healthcare environment. The treatment of pediatric and adult AAD is similar(discontinuing or switching the inciting antibiotic), but other treatment strategies for AAD have not been established. Pediatric CDI responds better to metronidazole, while adult CDI responds better to vancomycin. Recurrent CDI is not commonly reported for children. Prevention for both pediatric and adult AAD and CDI relies upon integrated infection control programs, antibiotic stewardship and may include the use of adjunctive probiotics. Clinical presentation of pediatric AAD and CDI are different than adult AAD and CDI symptoms. These differences should be taken into account when rating severity of disease and prescribing antibiotics. | Lynne Vernice Mc Farland Metehan Ozen Ener Cagri Dinleyici Shan Goh | 2016 | World Journal of Gastroenterology2016，22，11： | 39 |
| 2 | Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis显示文摘瞄准:评估反应到 pegylated 干扰素高山哈在长期的血液透析上的长期的丙肝病人的 2a。方法:有长期的 C 肝炎的十个病人在这研究被注册。所有为超过 6 瞬间,积极 antiHCV 抗体和积极 PCR HCV-RNA 增加了 aminotransferases。我们管理了木钉干扰素高山哈 2a 为 48 wk 的 180 microg/wk。在治疗的 12 wk 以后,我们评估了生物化学、早的 virological 反应(EVR ) 。在治疗的结束,我们在我们评估了的治疗的结束以后评估了生物化学的反应和 24 wk 持续 virological 反应(SVR ) 。我们在治疗期间监视了副作用。结果:二个病人在治疗的开始的 12 wk 放弃了并且 2 在治疗的开始的 12 wk 以后。在治疗的 12 wk 以后, 7 从 8 个病人有生物化学的反应和 EVR, 1 有生物化学的反应但是坚持的病毒血。我们不得不在 2 种情况中把 pegylated 干扰素的剂量归结为 135 mug/wk。三(50%) 从 6,病人们在治疗的结束以后有 SVR 24 wk。Intention-to-treat 分析证明 3 从 10 个病人(30%) 有 SVR。副作用发生在大多数病人(像流感的症候群,血小板减少或 leucopoenia ) ,但是他们没强加治疗的中止。结论:在有木钉干扰素高山的治疗的 12 wk 以后哈在有长期的 C 肝炎的长期的血液透析上的病人的 2a (40 ku ) , EVR 在 87.5% 被获得(7/8 ) 盒子。SVR 在完成了治疗的 48 wk 的 50% 盒子(3/6 病人) 中被完成。 | Ioan Sporea Alina Popescu Roxana ■irli Ovidiu Golea CameliaTotolici Mirela Dǎnilǎ Corina Vernic | 2006 | World Journal of Gastroenterology2006，12，26： | 2 |
| 3 | The impact on ruin probabilities of the association structure among financial risks显示文摘 | TANG Qi-he VERNIC R | 2007 | Statistics and Probability Letters2007，77，： | 1 |
| 4 | On a multivariate Pareto distribution显示文摘 | Asimit A V Furman E Vernic R | 2010 | Insurance: Mathematics and Economics2010，46，： | 1 |
| 5 | The MPTP model of Parkinson's diseases显示文摘 | RICHARD JS VERNICE JL | 2005 | Moheular Brain Research2005，，134： | 1 |
| 6 | Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Patients Aged 80 Years and Older: The tPA Stroke Survey Experience显示文摘 | David Tanne Mark J. Gorman Vernice E. Bates Scott E. Kasner Phillip Scott Piero Verro Jeffrey R. Binder Jeffrey M. Dayno Lonni R. Schultz Steven R. Levine | 2000 | Stroke: Journal of the American Heart Association2000，，2： | 1 |
| 7 | The effect of steroids on lymphocyte profile in primary chronic glomerulonephritis. Empirical or tailored therapy?显示文摘 | Cristina Gluhovschi Gheorghe Gluhovschi Diana Herman Elena Potencz Virginia Trandafirescu Adalbert Schiller Ligia Petrica Silvia Velciov Gheorghe Bozdog Flaviu Bob Calin Muntean Corina Vernic Valentin Guset Daniel Cioca | 2007 | International Immunopharmacology2007，，9： | 1 |
| 8 | The MPTP model of Parkinson's dis- ease 显示文摘 | Richard JS Vernice JL | 2005 | Molecular Brain Research2005，134，1： | 1 |
| 9 | The MPTP model of Parkinson(s) disease显示文摘 | Richarld Jay Smeyne Vernice Jackson-Lewis | 2005 | Molecular Brain Research2005，，134： | 1 |
| 10 | Asymptotics for risk capital allocations based on conditional tail expectation 显示文摘 | Tang Q Vernic R | 2011 | Insurance:Mathematics and Ecomomics2011，49，3： | 1 |
| 11 | Intravenous tissut-type plasminogen activator for freatment of acute stroke显示文摘 | Gregory W Vernice E Wayne M | 2000 | TAMA2000，283，： | 1 |
| 12 | TheMPTPmodel of Parkinsons' disease 显示文摘 | Richard Jay Smeyne Vernice Jackson-Lewis | 2005 | MolecularBrain Research2005，，134： | 1 |
| 13 | The MPTP model of Parkinson's disease显示文摘 | RICHARD J S VERNICE J L | 2005 | Molecular Brain Research2005，134，1： | 1 |
| 14 | Recursive evaluation of some bivariate compound distributions 显示文摘 | Vernic R | 1999 | Astin Bulletin1999，29，2： | 1 |
| 15 | Multivariate skew-normal distributions with applications in insurance显示文摘 | Raluca Vernic | 2005 | Insurance Mathematics and Economics2005，，2： | 1 |
| 16 | The impact on ruin probabilities of the association structure among finacial risks显示文摘 | Tang Q Vernic R | 2007 | Statistic and Probability Letters2007，77，： | 1 |
| 17 | Role of the neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-in-duced dopaminergic neurotoxicity显示文摘 | Vernice Jackson-Lewis Rina Yokoyama | 1996 | Proceedings of the National Academy Sciences of the United States of America1996，93，： | 1 |
| 18 | Role of neuronal ni- tric oxide in 1- methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine ( MPTP ) - induced dopaminergie neurotoxicity 显示文摘 | SERGE P VERNICE J L RINA Y | 1996 | PANS1996，93，： | 1 |
| 19 | The MPTP model of Parkinson's disease显示文摘 | Richard JS Vernice JL | 2005 | Mol Brain Res2005，134，1： | 1 |
| 20 | The MPTP model of Parkinson’s disease显示文摘 | RICHARD J S VERNICE J L | 2005 | Molecular Brain Research2005，134，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员